A cell therapy biotech needed the right CRO for a Phase 2 hematology study. Seuss+ cut contract negotiation by 1.5 months and recovered €2 million.
Contract Negotiation Client Impact Projects
Learn more here about our client impact projects in Contract Negotiation services for biotech, pharma, and CROs.
Selecting CROs Across the US and Australia for a Phase 2 CNS Study
A small biotech compared US and Australian CROs for a Phase 2 orphan CNS study. The result: an Australian CRO leading, in partnership with a US CRO.
Selecting the Right CRO for a Phase 2 Orphan Disease CNS Study
An early-stage biotech needed the right CRO for a Phase 2 orphan CNS study. Seuss+ ran RFI to contract, and the CRO was selected in four months.
Negotiating Sponsor-Friendly Contracts that Drive CRO Accountability & Performance
A privately-owned rare disease biotech preparing for a global Phase 3 clinical trial faced significant contract challenges with its CRO. Misaligned terms created limited leverage to enforce performance, slow responsiveness to operational issues, and exposure to budget overruns. Seuss+ was engaged to renegotiate contracts, protect the sponsor’s position, and establish governance structures to hold the CRO accountable.
Driving Clinical Trial Success in CNS – Pivotal Phase 3 Study
A privately-owned clinical-stage biotechnology company, focused on developing therapies for CNS indications, faced the high-stakes challenge of running a pivotal Phase 3 clinical trial for its lead asset. Partnering with a small CRO experienced in the disease area but inexperienced in complex global trials posed significant risks to operational delivery and future asset value. Seuss+ was engaged to optimize vendor alignment, governance, and inspection readiness to ensure trial success.
Driving Clinical Trial Success in Rare Diseases A Global Phase 3 Study
A privately-owned biotechnology company, backed by leading life science investors and over £270M in private financing, faced significant challenges running a global Phase 3 rare disease trial with a large CRO. With slow site activation, recruitment delays, and increasing board concerns over study feasibility, the sponsor engaged Seuss+ to restore confidence, accelerate timelines, and protect budget integrity.
CRO Selection & Governance for a Phase 3 Asthma Program
Avillion, a late-phase therapeutic project partner accelerating market availability, required guidance for CRO selection across two clinical trials. With ambitious delivery timelines and multiple suppliers involved, Avillion needed both robust vendor selection and a governance framework to manage multiple CROs effectively.
Fully-Integrated Vendor Management Support in Phase 2
A high-potential biotech, entering Phase 2 with an ambitious formulation study, faced late-stage strategic changes that rendered its original CRO unsuitable. Operating with a lean team and under competitive pressures, the sponsor required rapid CRO transition, complete vendor oversight, and embedded operational expertise to stay on schedule and protect data integrity.
We can help you
